Real-World Use, Effectiveness and Safety of Romiplostim, Eltrombopag and Avatrombopag in Immune Thrombocytopenia: Data from the Norwegian ITP Registry

埃尔特罗姆博帕格 罗米普洛斯蒂姆 医学 中止 血小板生成素 内科学 免疫性血小板减少症 血小板 临床终点 免疫学 随机对照试验 遗传学 干细胞 造血 生物
作者
Riccardo Tomasello,Lamya Garabet,Heidi Hassel Pettersen,Eirik Tjønnfjord,Galina Tsykunova,T. Lindhardt Pedersen,Hoa Tran,Mariasanta Napolitano,Waleed Ghanima
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 3952-3952
标识
DOI:10.1182/blood-2023-182848
摘要

Introduction: Thrombopoietin receptor agonists (TPO-RAs) are among the most widely used second-line treatments for immune thrombocytopenia (ITP). TPO-RAs counterbalance platelet destruction by stimulating proliferation and maturation of the megakaryocytes. Response rates varies between 60-90% and in the majority of cases continuous treatment with TPO-RAs is required to maintain response. However, it has recently been shown that 10-30% of patients can maintain response after treatment discontinuation (sustained response off-therapy - SROT). Romiplostim, Eltrombopag, and Avatrombopag are 3 TPO-RAs licensed for use in ITP in many countries. However, there is a lack of comparative studies on the efficacy and safety of these agent. Aims: To describe real-world use, effectiveness (rates of initial response, durable response, discontinuation and SROT) and safety of TPO-RAs in Norway for each of the 3 agents. Methods: This is a multicenter, retrospective/prospective study based on data from Norwegian ITP Registry (NOR-ITP). We identified all patients with primary ITP who had received at least one TPO-RA during the course of their disease (n=87). These patients were diagnosed with ITP between 1966 and 2023 and were included in NOR-ITP between 2016 and May 2023. We defined response to treatment as platelet count > 30*10 9/L and double than baseline and absence of bleeding, and complete response as platelet count > 100*10 9/L; time to response as the time to obtain response; durable response as 2 consecutive platelet counts > 30*10 9/L at 6 months without other therapies for ITP; SROT as response for at least 6 months in absence of any therapy for ITP after the discontinuation of TPO-RA. We reported adverse events as registered in NOR-ITP. We stratified the first TPO-RA agents by year ranges (2009 to 2019, 2019 to 2022, and 2022-2023) to evaluate tendency in choice of first agent and treatment line in which first TPO-RA was used. Results: Median (Q1; Q3) age of 87 ITP patients at the time of first TPO-RA was 60 years (38; 68); M:F ratio = 1:1. Phase of ITP in which the first TPO-RA was initiated was newly diagnosed in 14 (16%), persistent in 15 (17%), and chronic in 58 (67%) patients. As first TPO-RA, 23 (26%) received Romiplostim, 50 (57%) Eltrombopag, and 14 (17%) Avatrombopag. As shown in Figure1a, TPO-RAs are increasingly used in in the first and second line in ITP. Eltrombopag was the most widely used agent during 2009-2019, but the use declined from 2019-2022, while the use of Avatrombopag increased to become the mostly used agent in 2022-2023 (Figure1b). Response to first TPO-RA was achieved in 70% (16) for Romiplostim, 68% (35) for Eltrombopag, and 100% (14) for Avatrombopag. A complete response was achieved by 61% (14) for Romiplostim, 56% (28) for Eltrombopag, and 100% (14) for Avatrombopag. Median (Q1; Q3) time to response in days from start of TPO-RA was 7 (5;12) for Romiplostim, 10 (7;14) for Eltrombopag, and 7 (4;14) for Avatrombopag. Durable response rate (at 6 months) was 52% (n=12) for Romiplostim, 74% (n=37) for Eltrombopag, and 64% (n=9) for Avatrombopag. Reasons for discontinuation of Romiplostim were remission in 7 (30%) cases, absence or loss of response in 9 (40%), and was ongoing or discontinued for other reasons in 7 (30%); Eltrombopag was discontinued because of remission in 18 (36%) cases, absence or loss of response in 9 (18%), and was ongoing or discontinued for other reasons in 23 (46%). Avatrombopag was discontinued for remission in 4 (29%) cases, absence or loss of response in 3 (21%), and was ongoing or discontinued for other reasons in 7 (50%). SROT was obtained in 2 (9%) cases for Romiplostim, and 3 (6%) for Eltrombopag. Median duration of SROT was 13 (13; 44) months. Side effects were reported in 22 (25%) patients, 4 fatigue (5%), 2 bone marrow fibrosis (2%), and 2 thrombosis (2%). Conclusion: Our results show a comparable effectiveness between the three agents, however, a pattern of use of first TPO-RA is changing, and it appears to be slowly turning towards Avatrombopag. This trend is supported by current recommendations from Norwegian medicine funding authority towards Avatrombopag as first choice. Moreover, trust of clinicians towards TPO-RAs is increasing in recent years, as these agents begin to be chosen in earlier lines. Safety profiles were excellent, thrombosis and bone marrow fibrosis were rarely found.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
直率的问筠完成签到,获得积分10
2秒前
不发SCI不改名完成签到,获得积分10
2秒前
3秒前
4秒前
柯睿渊完成签到,获得积分10
4秒前
独特乘云完成签到,获得积分10
4秒前
贾克斯发布了新的文献求助10
4秒前
tlh完成签到 ,获得积分10
5秒前
陈彦滨完成签到 ,获得积分10
5秒前
6秒前
8秒前
8秒前
css完成签到,获得积分10
8秒前
Liufgui应助Re采纳,获得20
8秒前
Nugget完成签到,获得积分10
8秒前
yar应助潇湘雪月采纳,获得10
9秒前
宇宇发布了新的文献求助10
9秒前
shufessm完成签到,获得积分0
11秒前
11秒前
15秒前
幸福大白发布了新的文献求助30
15秒前
16秒前
肿瘤柳叶刀完成签到,获得积分10
17秒前
18秒前
18秒前
xxddw发布了新的文献求助10
19秒前
21秒前
GS11完成签到,获得积分10
22秒前
邓紫依完成签到,获得积分10
23秒前
cdytjt发布了新的文献求助60
23秒前
ai zs发布了新的文献求助10
23秒前
搜集达人应助zyw采纳,获得10
24秒前
25秒前
攀攀完成签到,获得积分10
26秒前
26秒前
Aprilapple发布了新的文献求助10
27秒前
张雯思发布了新的文献求助10
27秒前
28秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3989406
求助须知:如何正确求助?哪些是违规求助? 3531522
关于积分的说明 11254187
捐赠科研通 3270174
什么是DOI,文献DOI怎么找? 1804901
邀请新用户注册赠送积分活动 882105
科研通“疑难数据库(出版商)”最低求助积分说明 809174